Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Prof Kathie Knights Publications 1990-2010 Sallustio, B.C., Knights, K.M., and Meffin, P.J. The stereospecific inhibition of endogenous triacylglycerol synthesis by fenoprofen in rat isolated adipocytes and hepatocytes. Biochem. Pharmacol. 40: 1414-1417 (1990) Knights, K.M., Addinall, T.F., and Roberts, B.J. Enhanced chiral inversion of R-ibuprofen in liver from rats treated with clofibric acid. Biochem Pharmacol. 41: 1775-1777 (1991). Sallustio, B.C., Knights, K.M., Roberts, B.J., and Zacest, R. In vivo covalent binding of clofibric acid to human plasma proteins and rat liver proteins. Biochem. Pharmacol. 42: 1421-1425 (1991). Knights, K.M., and Jones, M.E. Inhibition kinetics of hepatic microsomal long chain fatty acid CoA ligase by 2arylpropionic acid non-steroidal anti-inflammatory drugs. Biochem. Pharmacol. 43: 1465-1471 (1992). Roberts, B.J., and Knights, K.M. Inhibition of rat peroxisomal palmitoyl-CoA ligase by xenobiotic carboxylic acids. Biochem. Pharmacol. 44: 261-267 (1992). Knights, K.M., and Drew R. Effects of ibuprofen enantiomers on rat hepatocyte intermediary metabolism. Biochem. Pharmacol. 44: 1291-1296 (1992). Knights, K.M., Talbot, U.M., and Baillie, T.A. Evidence of multiple forms of rat liver microsomal coenzyme A ligase catalysing the formation of 2-arylpropionyl-coenzyme A thioesters. Biochem. Pharmacol. 44: 2415-2417 (1992). Knights, K.M., McLean, C.F., Tonkin, A.L., and Miners, J.O. Lack of effect of gender and oral contraceptive steroids on the pharmacokinetics of R-ibuprofen in humans. Br. J. Clin. Pharmacol. 40: 153-156 (1995). Roberts, B.J., MacLeod, J.K., Singh, I., and Knights, K.M. Kinetic characteristics of rat liver peroxisomal nafenopincoenzyme A ligase. Biochem. Pharmacol. 49: 1335-1339 (1995). Roberts, B.J., and Knights, K.M. Differential induction of rat hepatic microsomal and peroxisomal long-chain and nafenopin-CoA ligases by clofibric acid and di-(2-ethylhexyl)phthalate. Xenobiotica 25: 469-476 (1995). Knights, K.M., and Roberts, B.J. Xenobiotic acyl-CoA formation: evidence of kinetically distinct hepatic microsomal long-chain fatty acid and nafenopin-CoA ligases. Chemico-Biol. Interactions 90: 215-223 (1994). Knights, K.M., McLean, C.F., Tonkin, A.L., and Miners, J.O. Lack of effect of gender and oral contraceptive steroids on the pharmacokinetics of R-ibuprofen in humans. Br. J. Clin. Pharmacol. 40: 153-156 (1995). Roberts, B.J., MacLeod, J.K., Singh, I., and Knights, K.M. Kinetic characteristics of rat liver peroxisomal nafenopincoenzyme A ligase. Biochem. Pharmacol. 49: 1335-1339 (1995). Roberts, B.J., and Knights, K.M. Differential induction of rat hepatic microsomal and peroxisomal long-chain and nafenopin-CoA ligases by clofibric acid and di-(2-ethylhexyl)phthalate. Xenobiotica 25: 469-476 (1995). Mackenzie, P.I., Anders, M.W., Yamazoe, Y., Weinshilboum, R.M., Knights, K.M., and Caldwell, J. Drug conjugation: Diversity and Biological Significance p161-168 in Pharmacological Sciences Perspectives for Research and Therapy in the late 1990s ed by A.C. Cuello & B. Collier, Birkhauser Verlag Basel/Switzerland (1995). Knights, K.M (Invited Review). Role of Hepatic Fatty acid:Coenzyme A Ligases in the Metabolism of Xenobiotic Carboxylic acids. Clin.Exp.Pharmacol.Physiol. 25: 776-782 (1998) Knights K.M. NSAIDs, from selective to specific. Aus. Musc. Med. 5:17-20 (2000). Knights K.M. and Drogemuller C.J. Xenobiotic-CoA ligases: Kinetic and Molecular Characterisation. Current Drug Metabolism. 1: 49-66 (2000) Sallustio B.C., Nunthasomboon S, Drogemuller C. J. and Knights K. M. In vitro covalent binding of nafenopin-CoA to human liver proteins. Toxicol. Appl. Pharmacol. 163:176-182 (2000) Knights K.M., Gasser R., and Klemisch W. In vitro metabolism of acitretin by human liver microsomes: Evidence of acitretinoyl-coenzyme A thioester conjugate in the transesterification to etretinate. Biochem Pharmacol. 60: 507-516 (2000) Prof Kathie Knights Publications 1990-2010 Drogemuller, C.J., Nunthasomboon S., and Knights K.M. Nafenopin-, ciprofibroyl-, and palmitoyl-CoA conjugation in vitro: Kinetic and molecular characterization of marmoset liver microsomes and expressed MLCL1. Arch. Biochem. Biophys. 396: 56-64. (2001) Tsoutsikos, P., Miners, J.O., Stapleton, A., Thomas, A., Sallustio, B.C. and Knights, K.M. Evidence that unsaturated fatty acids are potent inhibitors of renal UDP-glucuronosyltransferases (UGT): Kinetic studies using human kidney cortical microsomes and recombinant UGT1A9 and UGT2B7. Biochem. Pharmacol 67: 191-199 (2004). Bowalgaha, K., Elliot, D.J., Mackenzie, P.I., Knights, K.M., Swedmark, S. and Miners, J.O. S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDPglucuronosyltransferases (UGT): Role of UGT2B7 in the elimination of naproxen. Brit. J. Clin. Pharm. 60: 423-433 (2005). Knights, K.M., Mangoni, A.A. and Miners, J.O. Non-selective nonsteroidal anti-inflammatory drugs and cardiovascular events: is aldosterone the silent partner in crime? Br. J. Clin. Pharmacol. 61: 738-740 (2006). Miners, J.O., Knights, K.M., Houston, J.B., and Mackenzie, P.I. In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: Pitfalls and promises. Biochem. Pharmacol. 71: 1531-1539 (2006) 4 Bowalgaha, K., Elliot, D.J., Mackenzie, P.I., Knights, K.M. and Miners, J.O. The glucuronidation of ∇ -3-keto C19- and C21-hydroxysteroids by human liver microsomal and recombinant UDP-glucuronosyltransferases (UGTs): 6 - and 21-hydroxyprogesterone are selective substrates for UGT2B7. Drug Metab. Dispos. 35: 363-370 (2007). Gaganis, P., Miners, J.O. and Knights, K.M. Glucuronidation of fenamates: kinetic studies using human kidney cortical microsomes and recombinant UDP-glucuronosyltransferase (UGT) 1A9 and 2B7. Biochem. Pharmacol. 73: 16831691 (2007). Rowland, A., Gaganis, P., Elliot, D.J., Mackenzie P.I., Knights, K.M. and Miners, J.O. Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: Implications for in vitro-in vivo extrapolation. JPET 321: 137-147 (2007). Knights, K.M., Sykes, M.J., Miners, J.O. Amino acid conjugation: contribution to the metabolism and toxicity of xenobiotic carboxylic acids. Expert Opin Drug Met. 3: 159-168 (2007) Gaganis, P., Miners, J.O., Brennan, J.S., Thomas, A. and Knights, K.M. Human renal cortical and medullary UDPglucuronosyltransferases (UGTs): Immunohistochemical localization of UGT2B7 and UGT1A enzymes and kinetic characterization of S-naproxen glucuronidation. JPET 323: 1-9 (2007). Rowland, A., Elliot, D.J., Knights, K.M., Mackenzie, P.I. and Miners, J.O. The ‘albumin effect’ and in vitro – in vivo extrapolation: Sequestration of long chain unsaturated fatty acids enhances phenytoin hydroxylation by human liver microsomes and recombinant cytochrome P450 2C9. Drug Metab Dispos 36: 870-877 (2008). Rowland, A., Knights, K.M., Mackenzie, P.I. and Miners, J.O. The ‘albumin effect’ and drug glucuronidation: Bovine serum albumin and fatty acid free human serum albumin enhance the glucuronidation of UGT1A9 substrates but not UGT1A1 and UGT1A6 activities. Drug Metab Dispos 36:1056-1062 (2008). Kerdpin, O., Knights, K.M., Elliot, D.J. and Miners, J.O. In vitro characterisation of human renal and hepatic frusemide glucuronidation and identification of the UDP-glucuronosyltransferase enzymes involved in this pathway. Biochem. Pharmacol. 76: 249-257 (2008) Rowland, A., Knights, K.M., Mackenzie, P.I., and Miners, J.O. Characterization of the Binding of Drugs to Human Intestinal Fatty Acid Binding Protein (IFABP): Potential Role of IFABP as an Alternative to Albumin for in Vitro-in Vivo Extrapolation of Drug Kinetic Parameters. Drug Metab Dispos 37: 1395-1403 (2009). Doogue, M.P., and Knights, K.M. What changes are needed to the current direction and interpretation of clinical st cancer research to meet the needs of the 21 century? Med. J Aus. 191: 190-190 (2009). Knights, K.M., Winner, L.K., Elliot, D.J., Bowalgaha, K., and Miners, J.O. Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: Inhibition by NSAIDs. Br. J. Clin. Pharmacol. 68: 402-412 (2009). Prof Kathie Knights Publications 1990-2010 Miners, J.O., Mackenzie, P.I., and Knights, K.M. The prediction of drug-glucuronidation parameters in humans: UDPglucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential. Drug Metab Rev. 41: 196-208 (2010) Knights, K.M., and Miners, J.O. Renal UDP-glucuronosyltransferases and the glucuronidation of xenobiotics and endogenous mediators. Drug Metab Rev. 42: 63-73 (2010)